“drugs” Archives

in
Entry Author Date Location
First-Quarter Venture Funding Slumps in San Diego, and Top 10 Deals 04/06/17 San Diego
Gedeon Richter Gets Ex-U.S. Rights for Evestra Urological Product 04/06/17 Texas
Stealthy San Diego-based Viracta Steps Into Light with $18.5M 04/04/17 San Diego
New Blood: Biotech CEOs Bring Fresh Experience to Houston Ecosystem 04/03/17 Texas
Catalia’s Big-Eyed Robots Soon Will Nudge Patients To Take Their Meds 03/31/17 San Francisco
With New Data, Vertex Touts Backbone Of Future Cystic Fibrosis Drugs 03/28/17 Boston
IBRI, Dow Agrosciences, Lilly Partner on Molecular Safety Database  03/28/17 Indiana
After $1M NEI Grant, ONL Therapeutics Closer to Clinical Trials 03/27/17 Detroit Ann Arbor
Sanders, Cummings to PTC: Price Duchenne Steroid at Import Cost 03/22/17 New York
Texas Roundup: SXSW Odds & Ends, Dosh, Mythic, Peloton, & More 03/22/17 Texas
After a Clinical Trial Death, FDA OKs New Tests of Akashi’s Duchenne Drug 03/22/17 Boston
First Trial Underway, CytomX Gets $200M More In Expanded Bristol Pact 03/20/17 San Francisco
With New Data, Amgen Promises Refund If Cholesterol Drug Doesn’t Work 03/17/17 San Francisco
First Trial in Sight, Editas Cuts $90M Eye Drug Deal With Allergan 03/14/17 Boston
Scott Gottlieb On Tap to Lead FDA, and Biopharma Exhales 03/10/17 National
Vertex Bags Concert’s Rival CF Drug For $160M, Plans Combo Studies 03/06/17 Boston
No Details Yet, But Genentech Drug Combo Wins in Big Breast Cancer Study 03/02/17 San Francisco
Evestra Signs Deal with Glemark for Generic Version of NuvaRing 03/01/17 Texas
Medisafe Takes In $14.5M to Help Patients Manage Medications 03/01/17 Boston
FDA Approves Houston Biotech Lexicon’s Carcinoid Syndrome Diarrhea Drug 02/28/17 Texas
Nonprofit Seeds Exonics to Fund Push For CRISPR Duchenne Treatment 02/27/17 Boston
BioCrossroads Report: Steady Growth for Life Sciences in Indiana 02/24/17 Indiana
Aiming At P53, Cancer’s Hard Target, PMV Pharma Raises $74M 02/22/17 New York
Cashing in On Duchenne Approval, Sarepta Sells Voucher to Gilead For $125M 02/21/17 Boston
FDA Turmoil, Biology Mystery On List Of Hurdles For Microbiome Drugs 02/14/17 New York
Acorda Touts Success in Parkinson’s Drug Study, Awaits Safety Data 02/09/17 New York
Biotech Leaders Sign Letter Condemning Trump’s Travel Ban 02/07/17 National
No Details Yet, But Amgen Touts Success in Big Heart Drug Study 02/02/17 San Francisco
Insurer UHC Will Cover Biogen Spine Drug, But With Limits And Proof 02/02/17 Boston
Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths 02/01/17 Boston
Page 4 of 96 « previous page · next page »